Ables, Iannone, Moore & Associates, Inc. Amgen Inc Transaction History
Ables, Iannone, Moore & Associates, Inc.
- $155 Billion
- Q3 2024
A detailed history of Ables, Iannone, Moore & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Ables, Iannone, Moore & Associates, Inc. holds 3,364 shares of AMGN stock, worth $889,744. This represents 0.7% of its overall portfolio holdings.
Number of Shares
3,364
Previous 3,364
-0.0%
Holding current value
$889,744
Previous $1.05 Billion
3.12%
% of portfolio
0.7%
Previous 0.7%
Shares
2 transactions
Others Institutions Holding AMGN
# of Institutions
3,125Shares Held
409MCall Options Held
7.56MPut Options Held
7.2M-
Vanguard Group Inc Valley Forge, PA52.4MShares$13.9 Billion0.31% of portfolio
-
Black Rock Inc. New York, NY46MShares$12.2 Billion0.33% of portfolio
-
State Street Corp Boston, MA29.3MShares$7.75 Billion0.39% of portfolio
-
Morgan Stanley New York, NY14.7MShares$3.89 Billion0.35% of portfolio
-
Primecap Management CO Pasadena, CA14.3MShares$3.77 Billion3.44% of portfolio
About AMGEN INC
- Ticker AMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 534,931,008
- Market Cap $141B
- Description
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...